JP2000507346A - タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法 - Google Patents

タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法

Info

Publication number
JP2000507346A
JP2000507346A JP9523846A JP52384697A JP2000507346A JP 2000507346 A JP2000507346 A JP 2000507346A JP 9523846 A JP9523846 A JP 9523846A JP 52384697 A JP52384697 A JP 52384697A JP 2000507346 A JP2000507346 A JP 2000507346A
Authority
JP
Japan
Prior art keywords
tobacco
age
smoke
products
ages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9523846A
Other languages
English (en)
Japanese (ja)
Inventor
アントニー セラミー
リチャード ジェイ ブカラ
ヘレン ヴラッサラ
ヘンリー ダブリュー フォンズ
クララ ジェイ セラミ
Original Assignee
ザ ピコワー インスティテュート フォア メディカル リサーチ
アルテオン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ピコワー インスティテュート フォア メディカル リサーチ, アルテオン インコーポレイテッド filed Critical ザ ピコワー インスティテュート フォア メディカル リサーチ
Publication of JP2000507346A publication Critical patent/JP2000507346A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/365—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having nitrogen and sulfur as hetero atoms in the same ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
JP9523846A 1995-12-26 1996-12-23 タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法 Pending JP2000507346A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US921895P 1995-12-26 1995-12-26
US921995P 1995-12-26 1995-12-26
US60/009,219 1995-12-26
US60/009,218 1995-12-26
PCT/US1996/020526 WO1997023783A1 (fr) 1995-12-26 1996-12-23 Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion

Publications (1)

Publication Number Publication Date
JP2000507346A true JP2000507346A (ja) 2000-06-13

Family

ID=26679210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9523846A Pending JP2000507346A (ja) 1995-12-26 1996-12-23 タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法

Country Status (7)

Country Link
EP (1) EP0877943A1 (fr)
JP (1) JP2000507346A (fr)
CN (1) CN1211321A (fr)
AU (1) AU723649B2 (fr)
CA (1) CA2241924A1 (fr)
IN (1) IN191280B (fr)
WO (1) WO1997023783A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5921248A (en) * 1997-03-28 1999-07-13 The Picower Institute For Medical Research Tobacco combination product filter
EP1175155A4 (fr) * 1999-04-15 2005-10-19 Fox Chase Cancer Ct Procede destine a reduire la predisposition a la formation de tumeurs provoquees par la 3-desoxyglucosone et les precurseurs de cette substance
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
SE0400683D0 (sv) 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
CN106353434B (zh) * 2016-10-21 2018-10-09 中国烟草总公司郑州烟草研究院 一种定量测定烟草中Amadori化合物的分析方法
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN107202843B (zh) * 2017-06-07 2019-08-30 贵州省烟草科学研究院 LC-MS/MS法同时测定烟草中游离氨基酸和Amadori化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4827949A (en) * 1987-09-16 1989-05-09 Sunas Ernest C Method of treating tobacco and tobacco produced thereby
CA1332572C (fr) * 1988-01-29 1994-10-18 Anthony Cerami Methode et agents de prevention de la formation de taches sur les dents
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
CA2210684C (fr) * 1995-01-18 2008-01-15 Alteon Inc. Utilisation de composes de thiazolium pour empecher et inverser la formation de produits finis de glycosylation avancee

Also Published As

Publication number Publication date
CN1211321A (zh) 1999-03-17
EP0877943A1 (fr) 1998-11-18
AU723649B2 (en) 2000-08-31
CA2241924A1 (fr) 1997-07-03
WO1997023783A1 (fr) 1997-07-03
AU1345997A (en) 1997-07-17
IN191280B (fr) 2003-10-25

Similar Documents

Publication Publication Date Title
Quirynen et al. Characteristics of 2000 patients who visited a halitosis clinic
Schleicher et al. Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging.
Salonen et al. Serum copper and the risk of acute myocardial infarction: a prospective population study in men in eastern Finland
Geerts et al. Parental smoking and vascular damage in young adult offspring: is early life exposure critical? The atherosclerosis risk in young adults study
Scherer et al. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany
Giannopoulou et al. Effect of smoking on gingival crevicular fluid cytokine profile during experimental gingivitis
Moskowitz et al. Lipoprotein and oxygen transport alterations in passive smoking preadolescent children. The MCV Twin Study.
Glenn et al. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging
Mannan et al. Increased waist size and weight in relation to consumption of Areca catechu (betel-nut); a risk factor for increased glycaemia in Asians in east London
Podzolkov et al. Relation between tobacco smoking/electronic smoking and albuminuria/vascular stiffness in young people without cardiovascular diseases
Nomura et al. Association between work-related psychological stress and arterial stiffness measured by brachial-ankle pulse-wave velocity in young Japanese males from an information service company
US6110968A (en) Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5850840A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Holay et al. Effect of passive smoking on endothelial function in healthy adults
JP2000507346A (ja) タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法
Mizuno et al. Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men
WO1997023783A9 (fr) Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion
Ekman et al. Fenfluramine treatment of twenty children with autism
US5854000A (en) Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Christensen et al. Repeated validation of parental self‐reported smoking during pregnancy and infancy: a prospective cohort study of infants at high risk for allergy development
Mollashahi et al. Salivary sialic acid levels in smokeless tobacco users
Halmai et al. Cigarette smoke elicits relaxation of renal arteries
Korzeniowska et al. Homocysteine–relation to hypertension, age and smoking in patients with newly diagnosed essential hypertension
Lai et al. Biological toxicity of the compositions in electronic-cigarette on cardiovascular system
AU4252700A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts